We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email :PharmaSources@imsinoexpo.com
Whatsapp :+86-13621645194
Human Immunoglobulin (pH4) for Intravenous Injection (HUALAN))
Category:Bio Products > Protein/Antigen/Polypeptide > Other Protein Product Name:Human Immunoglobulin (pH4) for Intravenous Injection (HUALAN)) CAS No.:1 Standard:ChP Price(USD):Negotiable Company:Hualan Biological Vaccine Inc.
Factory Location: Xinxiang City, Henan Province, China
Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa
Sample Provided: no
Payment Terms: L/L
[Composition]
1. Human immunoglobulin is lgG.
2. Main Excipients: Maltose content: 90~110mg/ml, Polysorbate 80 content: Not higher than
100μg/ml.
[Characters]
It is a clear, colorless or light yellow liquid. Light opalescence may occur.
[Indications]
1.This product is suitable for treatment:
Primary immunoglobulin deficiency diseases, hypothyroidism such as X-linked hypoimmunoglobinemia, common variable immunodeficiency disease (CVID), IgG subclass deficiency, etc.
2. Secondary immunoglobulin deficiency diseases, such as severe infections, neonatal sepsis, etc.
3. Autoimmune diseases (AID), such as primary thrombocytopenic purpura, Kawasaki disease (KD), etc.
[Strengths]
2.5 g /vial (5%, 50 ml)
[Administration and Dosage]
Administration: inject i.v.gtt or i.v.gtt after diluted 1~2 folds with 5% glucose injection. The beginning dripping speed shall be 1.0 ml/min (approximately 20 drops/min). If no adverse reactions occur within the first 15 minutes, speed up gradually; but the maximum speed shall not exceed 3.0 ml/min (approximately 60 drops/min).